Compare HRMY & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRMY | VYX |
|---|---|---|
| Founded | 2017 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | HRMY | VYX |
|---|---|---|
| Price | $37.82 | $10.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $51.33 | $15.17 |
| AVG Volume (30 Days) | 695.1K | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | $825,944,000.00 | ★ $2,653,000,000.00 |
| Revenue This Year | $23.11 | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $7.55 |
| 52 Week High | $40.93 | $14.67 |
| Indicator | HRMY | VYX |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 53.55 |
| Support Level | $37.12 | $10.19 |
| Resistance Level | $39.60 | $10.62 |
| Average True Range (ATR) | 1.15 | 0.33 |
| MACD | -0.38 | 0.10 |
| Stochastic Oscillator | 17.33 | 75.56 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.